Navigation Links
Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
Date:11/10/2008

- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work

- "Let's Fight Flu Together!" initiative supports CDC's new vaccination recommendations which include children six months to 18 years old(1)

- Campaign goal is to increase vaccination rates while supporting PTA with a donation for those vaccinated

CAMBRIDGE, Mass., Nov. 10 /PRNewswire/ -- Novartis Vaccines announced today a national public health initiative for influenza vaccination for school-aged children, their families and teachers. In an effort to support the Centers for Disease Control and Prevention's (CDC) broader influenza vaccination recommendations, Novartis Vaccines has partnered with PTA (Parent Teacher Association) and Flu Busters, an on-site vaccinations provider, for a nationwide influenza vaccination campaign called "Let's Fight Flu Together!"

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novartis/35126/

During the 2008/2009 influenza season, "Let's Fight Flu Together!" vaccination clinics will be held for students and their families, teachers and community members at participating PTA schools and community sites across the United States. Children play a critical role in community-wide transmission of influenza, a recent study reported; and new recommendations from the CDC have increased the number of individuals advised to receive an annual influenza vaccination to include children from six months to 18 years of age.(1,2) Whereas previous recommendations included children from six months through 59 months of age, this new recommendation aims to help protect approximately 30 million additional children.(1,3)

"We are fully committed to supporting public health efforts to reduce the incidence of seasonal influenza and to protecting more people against this potentially deadly disease, especially our children," said Joerg Reinhardt, Chief Executive Officer of Novartis Vaccines. "Novartis Vaccines is proud to partner with PTA and Flu Busters on the "Let's Fight Flu Together!" initiative. Influenza has caused high rates of absenteeism among students and staff in our country's 119,000 schools.(4) Providing these accessible vaccination clinics will help bring influenza vaccines to as many families as possible, which we hope will result in keeping more children and teachers in school and parents at work this influenza season."

For each influenza vaccination administered by a Flu Busters' qualified health professional at a "Let's Fight Flu Together!" clinic, a donation will be made to PTA to support local students and schools. Each vaccination will cost $30, and Medicare Part B will be accepted from those who are eligible. Visitors to the clinics will also be able to receive tips on staying healthy during this influenza season. A comprehensive list of participating sites offering influenza vaccination clinics can be found at http://www.PTA.org/flushotclinics.

Many people think influenza, or "the flu," is just a bad cold. However, influenza can be a serious and potentially deadly virus.(5) On average each year, students miss approximately 38 million school days due to influenza and parents miss more than 10 million work days caring for these sick youngsters.(6,7) Moreover, during the last influenza season in the US, 83 children were reported who died from influenza-related causes.(8)

"PTA was founded on taking action for the health and wellness of children, parents, school staff and community members. That's why we're excited about returning to our roots with the help of Novartis Vaccines and Flu Busters," said Byron Garrett, Chief Executive Officer, National PTA. "In 2006, only 20 percent of school age children recommended to be vaccinated against seasonal influenza actually received the vaccine.(9) We hope that offering these clinics will make receiving an influenza vaccination convenient for people while educating them on the importance of preventing this potentially serious illness."

"People need to know that personal hygiene, such as washing your hands and good nutrition are only part of staying healthy during the influenza season," said Richard Kanowitz, President of Families Fighting Flu. "The single best protection against this potentially deadly disease is an annual influenza vaccination."(10)

Influenza vaccines are not currently approved for children under six months of age and may not prevent the disease in 100 percent of individuals receiving the vaccine.(11) Persons should consult their healthcare provider to determine if they have a condition that precludes them from receiving the vaccine. All vaccines have side effects. The most common side effects of influenza vaccinations include local reactions and mild general symptoms.(11)

For more information about the "Let's Fight Flu Together!" initiative, visit the PTA web site at http://www.PTA.org/flushotclinics.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "will", "committed", "potentially", "hope", "can", "may", or similar expressions, or by express or implied discussions regarding potential future revenues from the "Let's Fight Flu Together!" campaign. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the "Let's Fight Flu Together!" campaign will achieve any particular levels of revenue in the future. In particular, management's expectations regarding the "Let's Fight Flu Together!" campaign could be affected by, among other things, competition in general; government, industry and general public pricing pressures; unexpected manufacturing problems; unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

References

(1) Morbidity and Mortality Weekly Report, "Prevention and Control of Influenza, Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008," Accessed, September 18. 2008.

(2) Brownstein, J. S. & Mandl, K. Annals of Emergency Medicine, "Pediatric Population Size Is Associated With Geographic Patterns of Acute Respiratory Infections Among Adults." Volume 52, No. 1: July 2008.

(3) Centers for Disease Control and Prevention "CDC's Advisory Committee Recommends Influenza Vaccination for Children 6 months through 18 years of age" available at http://www.cdc.gov/media/pressrel/2008/r080227.htm. Accessed, September 18, 2008.

(4) Centers for Disease Control and Prevention "Stopping Germs at Home, Work and School" available at http://www.cdc.gov/germstopper/materials/home_work_school.pdf. Accessed, September 18, 2008.

(5) Centers for Disease Control and Prevention "Questions & Answers: Seasonal Influenza" available at http://www.cdc.gov/flu/about/qa/disease.htm. Accessed, September 18, 2008.

(6) Centers for Disease Control and Prevention, Vital and Health Statistics. "Current Estimates From the National Health Interview Survey, 1996." October 1999.

(7) Neuzil, K. M., Hohlbein, C. & Zhy, Y. Arch Pediatrics Adolescent Medicine. "Illness Among Schoolchildren During Influenza Season." Vol. 156, October 2002.

(8) Morbidity and Mortality Weekly Report, "Influenza Activity---United States and Worldwide, 2007-08 Season." Centers for Disease Control and Prevention. June 27, 2008 / 57(25); 692-697.

(9) 2006 National Consumer Study., June 2007.

(10) Centers for Disease Control and Prevention, "Key Facts About Seasonal Influenza (Flu)" available at http://www.cdc.gov/flu/keyfacts.htm. Accessed, September 18, 2008.

(11) Centers for Disease Control and Prevention, "Seasonal Flu Shots" available at http://www.cdc.gov/flu/about/qa/flushot.htm. Accessed, September 18, 2008.

Novartis Media Relations

Central media line: +41 61 324 2200

Eric Althoff Beth Birke

Novartis Global Media Relations Novartis Vaccines and Diagnostics

+41 61 324 7999 (direct) +1 (617) 871 4281 (direct)

+41 79 593 4202 (mobile) +1 (617) 803 4359 (mobile)

eric.althoff@novartis.com beth.birke@novartis.com

e-mail: media.relations@novartis.com

Novartis Investor Relations

Central phone: +41 61 324 7944

Ruth Metzler-Arnold +41 61 324 9980 North America:

Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433

John Gilardi +41 61 324 3018 Jill Pozarek +1 212 830 2445

Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456

Isabella Zinck +41 61 324 7188

e-mail: e-mail:

investor.relations@novartis.com investor.relations@novartis.com


'/>"/>
SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
4. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
5. Video: Prognosis Split for Hip Fracture and Hip Replacement in the Elderly
6. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
7. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
11. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):